Patents by Inventor Steven Robert Lee

Steven Robert Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL-2RBETA-SELECTIVE AGONISTS IN COMBINATION WITH AN ANTI-CTLA-4 ANTIBODY OR AN ANTI-PD-1 ANTIBODY
    Publication number: 20200368321
    Abstract: The invention relates to (among other things) a method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) administering an IL-2R?-activating amount of a long acting, IL-2R?-selective agonist; and (b) administering a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.
    Type: Application
    Filed: August 12, 2020
    Publication date: November 26, 2020
    Inventors: Murali Krishna Addepalli, Deborah H. Charych, Seema Kantak, Steven Robert Lee
  • Il-2R?-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody
    Patent number: 10786552
    Abstract: The invention relates to (among other things) a method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) administering an IL-2R?-activating amount of a long acting, IL-2R?-selective agonist; and (b) administering a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: September 29, 2020
    Assignee: Nektar Therapeutics
    Inventors: Murali Krishna Addepalli, Deborah H. Charych, Seema Kantak, Steven Robert Lee
  • IL-2RBETA-SELECTIVE AGONISTS IN COMBINATION WITH AN ANTI-CTLA-4 ANTIBODY OR AN ANTI-PD-1 ANTIBODY
    Publication number: 20180344810
    Abstract: The invention relates to (among other things) a method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) administering an IL-2R?-activating amount of a long acting, IL-2R?-selective agonist; and (b) administering a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.
    Type: Application
    Filed: June 4, 2018
    Publication date: December 6, 2018
    Inventors: Murali Krishna Addepalli, Deborah H. Charych, Seema Kantak, Steven Robert Lee
  • IL-2R?-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody
    Patent number: 10010587
    Abstract: The invention relates to (among other things) method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) an IL-2R?-activating amount of a long acting, IL-2R?-selective agonist; and (b) a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: July 3, 2018
    Assignee: Nektar Therapeutics
    Inventors: Murali Krishna Addepalli, Deborah H. Charych, Seema Kantak, Steven Robert Lee
  • IL-2RBETA-SELECTIVE AGONISTS IN COMBINATION WITH AN ANTI-CTLA-4 ANTIBODY OR AN ANTI-PD-1 ANTIBODY
    Publication number: 20170128539
    Abstract: The invention relates to (among other things) method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) an IL-2R?-activating amount of a long acting, IL-2R?-selective agonist; and (b) a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.
    Type: Application
    Filed: February 20, 2015
    Publication date: May 11, 2017
    Inventors: Murali Krishna Addepalli, Deborah H. Charych, Seema Kantak, Steven Robert Lee